AstraZeneca PLC (LON:AZN)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 170.36B |
| Revenue (ttm) | 42.56B |
| Net Income (ttm) | 6.02B |
| Shares Out | 1.55B |
| EPS (ttm) | 3.85 |
| PE Ratio | 28.56 |
| Forward PE | 16.01 |
| Dividend | 2.35 (2.14%) |
| Ex-Dividend Date | Feb 20, 2025 |
| Volume | 2,174,717 |
| Average Volume | 1,870,209 |
| Open | 10,906 |
| Previous Close | 10,986 |
| Day's Range | 10,818 - 10,978 |
| 52-Week Range | 9,574 - 13,388 |
| Beta | 0.17 |
| RSI | 55.54 |
| Earnings Date | Jul 29, 2025 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial numbers in USD Financial StatementsNews
5 Ideal 'Safer' Dividend Buys From Bloomberg's June Watch List
I highlight 15 dividend-paying stocks from Bloomberg's 50 Companies to Watch that meet my 'safer' criteria: free cash flow yields exceed dividend yields. The top ten dividend focus stocks offer an est...
AstraZeneca in deal with China firm worth up to £4bn
Astra has agreed a deal that could be worth almost £4billion with a Chinese company to use AI in the production of new treatments for chronic diseases.
AstraZeneca Inks China AI Research Deal For Chronic Diseases
British drugmaker AstraZeneca unveiled on Friday an AI-assisted research partnership with Chinese counterpart CSPC Pharmaceuticals worth up to $5.3 billion to tackle chronic diseases.
AstraZeneca signs research agreement with China's CSPC
AstraZeneca Inks Research Pact With China's CSPC Pharmaceuticals Focused On AI-Driven Research, Valued Up To $5.33 Billion
On Friday, AstraZeneca Plc (NASDAQ: AZN) entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group Limited . Per the agreement, AstraZeneca and CSPC agree to ...
AstraZeneca signs $5.2bn deal to develop drugs for chronic disease with Chinese biotech
Partnership gives group access to CSPC’s AI platform for discovering and optimising treatments
AstraZeneca signs US$5 billion research deal with China’s CSPC
AstraZeneca has signed a research agreement worth more than US$5 billion with Chinese drugmaker CSPC Pharmaceutical Group, the Anglo-Swedish drugmaker said on Friday.
AstraZeneca Teams Up With CSPC Pharmaceuticals With Deal Valued at Up to $5.33 Billion
The deal with China's CSPC Pharmaceuticals, focused on AI-driven research, aims to advance the discovery and development of new drug candidates.
AstraZeneca agrees to research deal worth up to $5.22 billion with CSPC
AstraZeneca said on Friday it has agreed to a research deal with Chinese drugmaker CSPC Pharmaceuticals worth up to $5.22 billion to focus on AI-enabled initiatives.
I attended the world's biggest cancer conference. Doctors gave standing ovations to 2 major breakthroughs.
Cancer researchers discovered how exercise really can be like a drug for colon cancer, and AstraZeneca is pioneering new ways to treat early disease.
Merck wins FDA nod for RSV shot for infants, challenging Sanofi/ AstraZeneca
What's Going On With IonQ Shares Monday?
IonQ, Inc. (NYSE: IONQ) shares traded higher Monday after the company announced results of a collaborative research program with AstraZeneca PLC (NASDAQ: AZN), Amazon Web Services and NVIDIA Corp (N...
FDA approves Mercks RSV shot for infants, ramping up competition with Sanofi and AstraZeneca
Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.
DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer
The first patient has been dosed in the DESTINY-Endometrial01 phase 3 trial evaluating ENHERTU ® (trastuzumab deruxtecan) in combination with rilvegostomig or pembrolizumab versus platinum-based chemo...
IonQ, AstraZeneca, Nvidia and AWS show quantum-accelerated drug development workflow
AstraZeneca: Fascinating Company With Lofty Ambitions - Just Not A Buy Yet
AstraZeneca’s £1 Billion Cambridge Hub Fuels UK Biotech Surge
AstraZeneca revealed its plan to establish a top-notch research centre in Cambridge today. The new facility hopes to strengthen the city’s status as a leader in biotech, spur innovation, and give more...
AstraZeneca CEO: We totally agree with President Trump on this
AstraZeneca CEO Pascal Soriot unpacks President Donald Trump's drug cost cut executive order on 'The Claman Countdown.' #foxbusiness #health #trump #maha
Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO
Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, Medicare patients.
AstraZeneca says Enhertu, Perjeta combo cuts death risk in breast cancer
AstraZeneca CEO Pascal Soriot on breast cancer drug trial
Pascal Soriot, CEO of AstraZeneca, said on Monday that he sees the pharma company's breast cancer blood test, which tracks signs of returning cancer, as "the future of cancer treatment."
AstraZeneca CEO on breast cancer drug trial: This is the future of cancer treatment
CNBC's Angelica Peebles and AstraZeneca CEO Pascal Soriot join 'Squawk Box' to discuss the company's breast cancer drug trial, the Trump administration's 'most favored nation' policy, R&D innovation, ...
AstraZeneca CEO on breast cancer drug trial: This is the future of cancer treatment
CNBC's Angelica Peebles and AstraZeneca CEO Pascal Soriot join 'Squawk Box' to discuss the company's breast cancer drug trial, the Trump administration's 'most favored nation' policy, R&D innovation, ...
How AstraZeneca Is Playing Its Cancer Cards To Become An $80 Billion Pharma
Three new cancer drugs could help AstraZeneca make a dent in its lofty ambition to become an $80 billion company by 2030.
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial
AstraZeneca and Daiichi Sankyo's ENHERTU plus pertuzumab showed a median progression-free survival greater than three years First trial in more than a decade to demonstrate an improvement in outcomes ...